<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8705</journal-id>
<journal-title><![CDATA[CES Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[CES Med.]]></abbrev-journal-title>
<issn>0120-8705</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87052023000100114</article-id>
<article-id pub-id-type="doi">10.21615/cesmedicina.7230</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Abordaje del Paciente con Sospecha de Cáncer Sólido. Revisión de tema]]></article-title>
<article-title xml:lang="en"><![CDATA[Approach to the Patient with Suspected Solid Cancer. Topic Review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribero-Vargas]]></surname>
<given-names><![CDATA[Marcel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zapata Muñoz]]></surname>
<given-names><![CDATA[Maycos Leandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correa-Parra]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Pablo Tobón Uribe  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Cancerología Las Américas Auna  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,IPS Coomsocial  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>37</volume>
<numero>1</numero>
<fpage>114</fpage>
<lpage>123</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87052023000100114&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87052023000100114&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87052023000100114&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  existe asociación entre el tiempo del diagnóstico y el pronóstico en pacientes con cáncer. El médico no oncólogo es quien establece el primer contacto con la persona, por lo que debe hacer un enfoque clínico adecuado.  Metodología:  se realizó una revisión narrativa en donde se hizo una búsqueda extensiva de la literatura en bases de datos (PubMed, Scopus, Web of Science), se seleccionaron los artículos más actualizados.  Enfoque:  se debe llevar a cabo una historia clínica, un examen físico completo y reconocer las posibles urgencias oncológicas. Para el tratamiento es mandatario tener confirmación histológica por lo que los esfuerzos deben estar dirigidos a este objetivo. El estudio del líquido pleural, pericárdico y peritoneal pueden aportar un diagnóstico histológico ágil y poco invasivo, que permita iniciar tratamiento. En caso de no tener efusiones, se deberá tomar biopsia de las lesiones más representativas y de más fácil acceso. Se debe evitar la toma rutinaria de estudios endoscópicos en pacientes sin síntomas de neoplasia gastrointestinal, al igual que marcadores tumorales que no son precisos y confunden en el proceso diagnóstico.  Conclusión:  es indispensable un enfoque clínico correcto que permita un diagnóstico preciso y oportuno.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  there is an association between time of diagnosis and prognosis in cancer patients. The non-oncologist physician is usually the first healthcare provider to establish contact with the patient, therefore, they must have an adequate clinical approach.  Methodology:  a narrative review was conducted, where an extensive search of the literature was performed in databases (PubMed, Scopus, Web of Science), and the most up-to-date articles were selected.  Approach: a complete medical history, a thorough physical examination, and the recognition of possible oncologic emergencies should be carried out. For treatment, histological confirmation is mandatory, and efforts should be directed towards achieving this goal. The study of pleural, pericardial, and peritoneal fluid can provide a quick and non-invasive histological diagnosis, allowing for the initiation of treatment. In cases where there are no effusions, biopsies should be taken from the most representative and easily accessible lesions. Routine endoscopic studies should be avoided in patients without symptoms of gastrointestinal neoplasia, as well as tumor markers that are not accurate and may confuse the diagnostic process.  Conclusion:  a correct clinical approach that allows for a precise and timely diagnosis is indispensable.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[neoplasias]]></kwd>
<kwd lng="es"><![CDATA[efusiones]]></kwd>
<kwd lng="es"><![CDATA[metástasis]]></kwd>
<kwd lng="en"><![CDATA[neoplasms]]></kwd>
<kwd lng="en"><![CDATA[effusions]]></kwd>
<kwd lng="en"><![CDATA[metastasis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hajioff]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt-Hansen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Suspected cancer (part 2 - Adults): Visual overview of updated NICE guidance]]></article-title>
<source><![CDATA[BMJ Publishing Group]]></source>
<year>2015</year>
<volume>350</volume>
<page-range>15-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Tharmanathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[France]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Din]]></surname>
<given-names><![CDATA[NU]]></given-names>
</name>
<name>
<surname><![CDATA[Cotton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fallon-Ferguson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review]]></article-title>
<source><![CDATA[British Journal of Cancer]]></source>
<year>2015</year>
<volume>112</volume>
<page-range>S92-107</page-range><publisher-name><![CDATA[Springer Nature]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berrino]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Gatta]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sant]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Capocaccia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EUROCARE study of survival of cancer patients in Europe: Aims, current status, strengths and weaknesses]]></article-title>
<source><![CDATA[European Journal of Cancer]]></source>
<year>2001</year>
<volume>37</volume>
<edition>6</edition>
<page-range>673-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC)</collab>
<source><![CDATA[Situación del cáncer en la población adulta atendida en el SGSSS de Colombia, 2021]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Bogotá, D. C. ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marzo-Castillejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vela-Vallespín]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overdiagnosis in cancer]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2018</year>
<volume>50</volume>
<page-range>51-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavlidis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pentheroudakis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer of unknown primary site: 20 questions to be answered]]></source>
<year>2010</year>
<publisher-name><![CDATA[In: Annals of Oncology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gould Rothberg]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Quest]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Yeung]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pelosof]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gerber]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Seltzer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncologic emergencies and urgencies: A comprehensive review]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2022</year>
<volume>72</volume>
<edition>6</edition>
<page-range>570-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klemencic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of oncologic emergencies. Vol. 20, Western Journal of Emergency Medicine]]></article-title>
<source><![CDATA[eScholarship]]></source>
<year>2019</year>
<page-range>316-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayuso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rimola]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vilana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Burrel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Darnell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Criado]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines]]></article-title>
<source><![CDATA[Eur J Radiol]]></source>
<year>2018</year>
<volume>101</volume>
<page-range>72-81</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shroff]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Guirguis]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Ocazionez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oldham]]></surname>
<given-names><![CDATA[SAA]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Chiles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond metastatic disease: A pictorial review of multinodular lung disease with computed tomographic pathologic correlation]]></article-title>
<source><![CDATA[Canadian Association of Radiologists Journal]]></source>
<year>2015</year>
<volume>66</volume>
<edition>1</edition>
<page-range>16-23</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Runyon]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Montano]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Akriviadis]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Antillon]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Irving]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[McHutchison]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites]]></article-title>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>1992</year>
<volume>117</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uehara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuhara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Motoi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sugawara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2020</year>
<volume>157</volume>
<edition>2</edition>
<page-range>398-404</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavazzoni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bugiantella]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Graziosi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Franceschini]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Donini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant ascites: Pathophysiology and treatment]]></article-title>
<source><![CDATA[International Journal of Clinical Oncology]]></source>
<year>2013</year>
<volume>18</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of optimal debulking surgery in ovarian cancer]]></article-title>
<source><![CDATA[Gland Surg]]></source>
<year>2021</year>
<volume>10</volume>
<edition>3</edition>
<page-range>1173-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Babu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lanjewar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jadhav]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Wagh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aurangabadkar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Upadhyay]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A case series of malignant pericardial effusion]]></article-title>
<source><![CDATA[J Family Med Prim Care]]></source>
<year>2022</year>
<volume>11</volume>
<edition>10</edition>
<page-range>6581</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burazor]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Imazio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Markel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant pericardial effusion]]></article-title>
<source><![CDATA[Cardiology (Switzerland)]]></source>
<year>2013</year>
<volume>124</volume>
<page-range>224-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Antelo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Dobaño]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Toubes]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Riveiro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant Pleural Effusion: Diagnosis and Management. Vol. 2020, Canadian Respiratory Journal]]></article-title>
<source><![CDATA[Hindawi Limited]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gayen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant Pleural Effusion: Presentation, Diagnosis, and Management]]></article-title>
<source><![CDATA[American Journal of Medicine]]></source>
<year>2022</year>
<volume>135</volume>
<page-range>1188-92</page-range><publisher-name><![CDATA[Elsevier Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blanc]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Debaillon-Vesque]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Barbare]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Boige]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)]]></article-title>
<source><![CDATA[Clin Res Hepatol Gastroenterol]]></source>
<year>2021</year>
<volume>45</volume>
<edition>2</edition>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heilbrun]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dechet]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Zagoria]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: Evidence from a markov model]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2012</year>
<volume>187</volume>
<edition>1</edition>
<page-range>39-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients]]></article-title>
<source><![CDATA[Thorac Cancer]]></source>
<year>2018</year>
<volume>9</volume>
<edition>11</edition>
<page-range>1453-60</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Sanoff]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer of unknown primary]]></article-title>
<source><![CDATA[The BMJ]]></source>
<year>2020</year>
<volume>371</volume>
<publisher-name><![CDATA[BMJ Publishing Group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Losa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Estival]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Giménez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SEOM clinical guideline on unknown primary cancer (2017)]]></article-title>
<source><![CDATA[Clinical and Translational Oncology]]></source>
<year>2018</year>
<volume>20</volume>
<edition>1</edition>
<page-range>89-96</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bochtler]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Löffler]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Krämer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of metastatic neoplasms with unknown primary]]></article-title>
<source><![CDATA[Seminars in diagnostic pathology]]></source>
<year>2018</year>
<volume>35</volume>
<edition>3</edition>
<page-range>199-206</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shreenivas]]></surname>
<given-names><![CDATA[A v.]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Skefos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sicklick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzrock]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma of unknown primary: Molecular tumor board&#8208;based therapy]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2022</year>
<volume>72</volume>
<edition>6</edition>
<page-range>510-23</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
